OpGen, Inc. (NASDAQ:OPGN – Get Free Report)’s stock price passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $4.12 and traded as low as $2.35. OpGen shares last traded at $2.36, with a volume of 11,959 shares trading hands.
Analyst Ratings Changes
Separately, StockNews.com assumed coverage on shares of OpGen in a report on Saturday, May 25th. They issued a “sell” rating on the stock.
Get Our Latest Report on OpGen
OpGen Stock Performance
Institutional Inflows and Outflows
An institutional investor recently bought a new position in OpGen stock. Chase Investment Counsel Corp acquired a new stake in shares of OpGen, Inc. (NASDAQ:OPGN – Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned about 2.63% of OpGen at the end of the most recent reporting period. 2.68% of the stock is currently owned by institutional investors.
OpGen Company Profile
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
Further Reading
- Five stocks we like better than OpGen
- The Most Important Warren Buffett Stock for Investors: His Own
- Darden Stock Up After Q4 Earnings Beat, Cautious FY25 Outlook
- 5 discounted opportunities for dividend growth investors
- Celsius Stock: Why Piper Sandler Forecasts a 50% Surge
- Industrial Products Stocks Investing
- Accenture’s Stock Earnings Reveal an AI-Powered Growth Strategy
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.